MX348827B - Miembro que enlaza al receptor gm-csf. - Google Patents
Miembro que enlaza al receptor gm-csf.Info
- Publication number
- MX348827B MX348827B MX2015007466A MX2015007466A MX348827B MX 348827 B MX348827 B MX 348827B MX 2015007466 A MX2015007466 A MX 2015007466A MX 2015007466 A MX2015007466 A MX 2015007466A MX 348827 B MX348827 B MX 348827B
- Authority
- MX
- Mexico
- Prior art keywords
- binding member
- csf receptor
- binding members
- receptor
- csfr
- Prior art date
Links
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 title 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La presente invención se refiere a miembros de enlace para una cadena alfa de receptor para el factor estimulante de colonia de macrófago de granulocito (GM-CSFRa), especialmente moléculas de anticuerpo. También se describe el uso de miembros de enlace en el tratamiento de enfermedades inflamatorias y autoinmunitarias, por ejemplo artritis reumatoide, asma, respuesta alérgica, esclerosis múltiple, leucemia mieloide y ateroesclerosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78656906P | 2006-03-27 | 2006-03-27 | |
PCT/GB2007/001108 WO2007110631A1 (en) | 2006-03-27 | 2007-03-27 | Binding member for gm-csf receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX348827B true MX348827B (es) | 2017-06-30 |
Family
ID=38293698
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008012291A MX2008012291A (es) | 2006-03-27 | 2007-03-27 | Miembro que enlaza al receptor gm-csf. |
MX2015007466A MX348827B (es) | 2006-03-27 | 2007-03-27 | Miembro que enlaza al receptor gm-csf. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008012291A MX2008012291A (es) | 2006-03-27 | 2007-03-27 | Miembro que enlaza al receptor gm-csf. |
Country Status (16)
Country | Link |
---|---|
US (8) | US8263075B2 (es) |
EP (3) | EP1999152B1 (es) |
JP (2) | JP5335662B2 (es) |
KR (2) | KR101481844B1 (es) |
CN (3) | CN101443360B (es) |
BR (1) | BRPI0709259B1 (es) |
CA (1) | CA2647449C (es) |
DK (3) | DK2423230T3 (es) |
ES (3) | ES2395839T3 (es) |
HK (2) | HK1166988A1 (es) |
MX (2) | MX2008012291A (es) |
PL (3) | PL2423230T3 (es) |
PT (3) | PT2423229E (es) |
RU (2) | RU2495050C2 (es) |
SI (3) | SI2423229T1 (es) |
WO (1) | WO2007110631A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101481844B1 (ko) * | 2006-03-27 | 2015-01-13 | 메디뮨 리미티드 | Gm-csf 수용체에 대한 결합 성분 |
CN105435223A (zh) * | 2006-11-21 | 2016-03-30 | 卡罗拜奥斯制药公司 | 使用gm-csf拮抗剂治疗慢性炎症疾病的方法 |
JP5608635B2 (ja) | 2008-04-07 | 2014-10-15 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 心不全処置のためのgm−csfの中和方法 |
AU2015224416B2 (en) * | 2008-12-22 | 2017-04-20 | The University Of Melbourne | Osteoarthritis treatment |
EP3381471B1 (en) | 2008-12-22 | 2024-03-20 | The University of Melbourne | Pain treatment |
CA2746827C (en) * | 2008-12-22 | 2018-01-23 | The University Of Melbourne | Osteoarthritis treatment |
SG175305A1 (en) * | 2009-04-23 | 2011-11-28 | Theraclone Sciences Inc | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
KR20140064943A (ko) * | 2009-05-05 | 2014-05-28 | 모르포시스 아게 | 다발성 경화증의 치료 |
US20120165220A1 (en) * | 2009-09-03 | 2012-06-28 | Colgan Sean P | Uses of CD116 Expression Level |
CN103906767A (zh) * | 2011-10-10 | 2014-07-02 | 米迪缪尼有限公司 | 对类风湿关节炎的治疗 |
WO2013072901A2 (en) * | 2011-11-17 | 2013-05-23 | Btm Mazowsze Sp. Zo.O. | Compositions and methods for treating glioma |
EP2602264A1 (en) | 2011-12-05 | 2013-06-12 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH | GDF-5 mutant for inducing cartilage formation |
WO2013090989A1 (en) | 2011-12-22 | 2013-06-27 | Csl Limited | Method of treating inflammatory bowel disease |
JP6339578B2 (ja) | 2012-10-31 | 2018-06-06 | タケダ・ゲー・エム・ベー・ハーTakeda GmbH | Gm−csf中和化合物を含む凍結乾燥製剤 |
AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
WO2014091034A1 (en) | 2012-12-14 | 2014-06-19 | Universitätsmedizin Der Johannes Gutenberg-Universität Mainz | Novel mhc-independent tumor-associated antigens |
CN103193882B (zh) * | 2013-03-29 | 2014-11-05 | 浙江大学 | 胚胎干细胞特异性标志物GM-CSFRα及其应用 |
MX2016002177A (es) | 2013-08-30 | 2016-06-28 | Takeda Gmbh | Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos. |
WO2015169742A1 (en) | 2014-05-07 | 2015-11-12 | Takeda Gmbh | Liquid formulation comprising gm-csf neutralizing compound |
US20170260276A1 (en) * | 2014-05-19 | 2017-09-14 | Medimmune Limited | Treatment for rheumatoid arthritis |
GB201503139D0 (en) * | 2015-02-25 | 2015-04-08 | Univ Leicester | Diagnostic and therapeutic target |
GB201519331D0 (en) * | 2015-11-02 | 2015-12-16 | Glaxosmithkline Ip Dev Ltd | Treatment paradigm |
AU2017270027A1 (en) | 2016-05-24 | 2018-12-06 | Medimmune Limited | Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis |
CA3235178A1 (en) | 2017-03-01 | 2018-09-07 | Medimmmune Limited | Formulations of monoclonal antibodies |
US11655293B2 (en) | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
EP3623382A1 (en) | 2018-09-14 | 2020-03-18 | Universität Zürich | Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct |
US11078264B2 (en) | 2018-10-17 | 2021-08-03 | University Of Connecticut | Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth |
WO2020096664A1 (en) | 2018-11-09 | 2020-05-14 | Kiniksa Pharmaceuticals, Ltd. | Treatment for giant cell arteritis |
WO2020097321A1 (en) | 2018-11-09 | 2020-05-14 | Kiniksa Pharmaceuticals, Ltd. | Treatment for giant cell arteritis |
JP7290725B2 (ja) * | 2018-11-27 | 2023-06-13 | 舒泰神(北京)生物製薬股フン有限公司 | 顆粒球-マクロファージコロニー刺激因子受容体αを特異的に認識する抗体及びその使用 |
US20220331425A1 (en) | 2019-06-03 | 2022-10-20 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cancers with gm-csf antagonists |
WO2021141986A1 (en) * | 2020-01-07 | 2021-07-15 | St. Jude Children's Research Hospital, Inc. | Chimeric gmcsf-il18 receptor |
WO2021188409A1 (en) | 2020-03-15 | 2021-09-23 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cytokine release syndrome with gm-csf antagonists |
WO2021204649A1 (en) | 2020-04-06 | 2021-10-14 | Glaxosmithkline Intellectual Property Development Limited | Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome |
CN111690063A (zh) * | 2020-05-25 | 2020-09-22 | 北京大学 | 一种抗gm-csf纳米抗体及其制备方法和应用 |
AU2021372454A1 (en) | 2020-10-26 | 2023-06-22 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cancers with gm-csf antagonists |
KR20230132470A (ko) | 2020-12-18 | 2023-09-15 | 키닉사 파마슈티컬스, 리미티드 | 단백질 조성물 및 이를 생산하는 방법 및 사용하는방법 |
WO2023138499A1 (zh) * | 2022-01-20 | 2023-07-27 | 舒泰神(北京)生物制药股份有限公司 | 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5629283A (en) * | 1989-08-11 | 1997-05-13 | Amrad Corporation Limited | Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof |
AU637133B2 (en) * | 1989-08-11 | 1993-05-20 | Amrad Operations Pty. Limited | Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1994009149A1 (en) * | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
CA2149881A1 (en) | 1992-11-19 | 1994-05-26 | Paul T. Jubinsky | Antibodies for gm-csf receptor and uses thereof |
DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
AUPN780096A0 (en) * | 1996-01-30 | 1996-02-22 | Medvet Science Pty. Ltd. | Cytokine antagonists and agonists |
ES2329959T5 (es) | 1998-12-10 | 2013-12-18 | Bristol-Myers Squibb Company | Armazones de proteína para miméticos de anticuerpo y otras proteínas de unión |
MXPA02008472A (es) | 2000-03-03 | 2004-03-26 | Cambridge Antibody Tech | Anticuerpos humanos contra la eotaxina y su uso. |
US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
KR100453877B1 (ko) * | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
MXPA04012656A (es) * | 2002-06-14 | 2005-08-15 | Immunomedics Inc | Anticuerpo hpam4 monoclonal humanizado. |
PL211180B1 (pl) * | 2002-12-17 | 2012-04-30 | Merck Patent Gmbh | Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków |
US20040146486A1 (en) * | 2003-01-24 | 2004-07-29 | Juan Sun | Hybrid vector system for use as a vaccine |
KR101481844B1 (ko) * | 2006-03-27 | 2015-01-13 | 메디뮨 리미티드 | Gm-csf 수용체에 대한 결합 성분 |
US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2007
- 2007-03-27 KR KR20087026232A patent/KR101481844B1/ko active IP Right Grant
- 2007-03-27 DK DK11167923.9T patent/DK2423230T3/da active
- 2007-03-27 CA CA2647449A patent/CA2647449C/en active Active
- 2007-03-27 PL PL11167923T patent/PL2423230T3/pl unknown
- 2007-03-27 ES ES07712963T patent/ES2395839T3/es active Active
- 2007-03-27 PT PT111679122T patent/PT2423229E/pt unknown
- 2007-03-27 PL PL11167912T patent/PL2423229T3/pl unknown
- 2007-03-27 US US11/692,008 patent/US8263075B2/en active Active
- 2007-03-27 CN CN2007800154169A patent/CN101443360B/zh active Active
- 2007-03-27 JP JP2009502208A patent/JP5335662B2/ja active Active
- 2007-03-27 US US12/294,616 patent/US8506960B2/en active Active
- 2007-03-27 EP EP07712963A patent/EP1999152B1/en active Active
- 2007-03-27 BR BRPI0709259-8A patent/BRPI0709259B1/pt active IP Right Grant
- 2007-03-27 SI SI200731285T patent/SI2423229T1/sl unknown
- 2007-03-27 DK DK07712963.3T patent/DK1999152T3/da active
- 2007-03-27 MX MX2008012291A patent/MX2008012291A/es active IP Right Grant
- 2007-03-27 CN CN201310562197.3A patent/CN103641916A/zh active Pending
- 2007-03-27 SI SI200731100T patent/SI1999152T1/sl unknown
- 2007-03-27 ES ES11167923T patent/ES2424468T3/es active Active
- 2007-03-27 PT PT77129633T patent/PT1999152E/pt unknown
- 2007-03-27 RU RU2008137763/10A patent/RU2495050C2/ru active
- 2007-03-27 WO PCT/GB2007/001108 patent/WO2007110631A1/en active Application Filing
- 2007-03-27 PT PT111679239T patent/PT2423230E/pt unknown
- 2007-03-27 DK DK11167912.2T patent/DK2423229T3/da active
- 2007-03-27 MX MX2015007466A patent/MX348827B/es unknown
- 2007-03-27 CN CN201310558011.7A patent/CN103641915B/zh active Active
- 2007-03-27 PL PL07712963T patent/PL1999152T3/pl unknown
- 2007-03-27 SI SI200731286T patent/SI2423230T1/sl unknown
- 2007-03-27 EP EP11167912.2A patent/EP2423229B1/en active Active
- 2007-03-27 ES ES11167912T patent/ES2424467T3/es active Active
- 2007-03-27 KR KR1020137029959A patent/KR101451546B1/ko active IP Right Grant
- 2007-03-27 EP EP11167923.9A patent/EP2423230B1/en active Active
-
2012
- 2012-08-02 HK HK12107633.4A patent/HK1166988A1/xx unknown
- 2012-08-03 HK HK12107671.7A patent/HK1166989A1/xx unknown
- 2012-12-26 RU RU2012157042A patent/RU2639546C2/ru active
-
2013
- 2013-01-10 JP JP2013002623A patent/JP5665894B2/ja active Active
- 2013-07-12 US US13/941,409 patent/US9085628B2/en active Active
-
2015
- 2015-06-29 US US14/753,792 patent/US20150376285A1/en not_active Abandoned
-
2018
- 2018-05-15 US US15/980,664 patent/US20190040145A1/en not_active Abandoned
-
2019
- 2019-01-08 US US16/242,850 patent/US20190309077A1/en not_active Abandoned
-
2020
- 2020-10-14 US US17/070,623 patent/US20210147559A1/en not_active Abandoned
-
2023
- 2023-10-31 US US18/499,051 patent/US20240124596A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX348827B (es) | Miembro que enlaza al receptor gm-csf. | |
EA017420B9 (ru) | Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека | |
CY2018013I1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
CY1120874T1 (el) | Συνθεση αντισωματος ιντερλευκινης-13 | |
DK1784426T3 (da) | Humaniserede anti-beta7-antagonister og anvendelser deraf | |
WO2010011944A3 (en) | Protein screeing methods | |
TW200744634A (en) | Methods of using antibodies against human IL-22 | |
EP2572734A3 (en) | Cytokine-based fusion proteins for treatment of immune disorders | |
IL198061A0 (en) | Antibody molecules whice bind il-17a and il-17f | |
HK1116398A1 (en) | Anti-il-6 antibodies, compositions, methods and uses il-6 | |
TN2011000052A1 (en) | Anti-il-12/il-23 antibodies | |
EP2604628A3 (en) | Binding members for interleukin-4 receptor alpha (IL-4R) - 173 | |
EP1853242A4 (en) | SMALL STAT3 INHIBITORY MOLECULES AND USES THEREOF | |
IL201281A0 (en) | Antibodies that bind both il - 17a and il-17f and methods of using the same | |
SI3002298T1 (sl) | Monoklonska protitelesa proti faktorju XI in postopki njihove uporabe | |
TN2009000181A1 (en) | Agonist trkb antibodies and uses thereof | |
TW200700726A (en) | Autoantibody detection for cancer diagnostics | |
EP2290077A3 (en) | Natural IGM antibodies and inhibitors thereof | |
MX2007013108A (es) | Reactivos que enlazan ccx-ckr2. | |
CY1115121T1 (el) | Μελος συνδεσης για τον ληπτη gm-csf | |
ATE522299T1 (de) | Zwei oder mehrlagige druckfeder | |
AU2005906549A0 (en) | Interleukin 10 receptor alpha and chimeric molecules thereof |